Origami Therapeutics / Longevity.Technology · Mar 2026
Interview with CEO Beth Hoffman about using autophagy and protein disposal pathways to target misfolded brain proteins; includes comments on Huntington’s disease and brain healthspan.
Oral drugs to halt neurodegeneration
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Origami Therapeutics, Inc. is a San Diego-based preclinical biotech developing small-molecule protein degraders and protein conformation correctors for neurodegenerative diseases, with a lead focus on Huntington’s disease through its ORICISION™ platform. Public sources conflict on founding year and total funding, so I used the most current company/profile signals and noted the discrepancy in the research.
Primary product
ORICISION™ small-molecule protein degrader/conformation-corrector platform, with lead program ORI-003 for Huntington’s disease
Founded
2016
Headquarters
San Diego, California, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Preclinical neurodegenerative-disease drug discovery / protein degradation therapeutics
Open Positions
0 jobs at Origami Therapeutics, Inc.
No open positions
Check back later for new openings